Comparative Pharmacology
Head-to-head clinical analysis: MEZOFY versus ZUPLENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEZOFY versus ZUPLENZ.
MEZOFY vs ZUPLENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MEZOFY is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
MEZOFY (mexiletine) 200 mg orally every 8 hours; may increase to 300 mg every 8 hours if needed.
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
None Documented
None Documented
Terminal half-life: 8-12 hours (mean 10 h); prolonged in renal impairment (up to 24 h in CrCl <30 mL/min)
Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours
Renal: 60% unchanged; biliary/fecal: 25% as metabolites; 15% other
Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized
Category C
Category C
Antiemetic/Antivertigo
Antiemetic